Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
GI Oncology Now
Bile Duct Cancer
Colorectal Cancer
Gastroesophageal Cancer
Gastric Cancer
GEP-NETs
GIST
Liver Cancer
Pancreatic Cancer
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Leah Lawrence
Leah Lawrence
Articles by Leah Lawrence
Trastuzumab Deruxtecan Approved for HER2-Low, Ultralow Metastatic Breast Cancer
Leah Lawrence
HER2 Breast Cancer
|
March 28, 2025
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
Read More
ADC Emi-Le Fast Tracked for HER2-Low/Negative Breast Cancer
Leah Lawrence
HER2 Breast Cancer
|
March 28, 2025
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Read More
CheckMate 77T Analysis Evaluates Perioperative Nivolumab in Resectable NSCLC
Leah Lawrence
ASCO 2024: Focus on Lung Cancer
|
July 10, 2024
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
Read More
Is Neoadjuvant Nivolumab Plus Chemotherapy Feasible for Resectable Diffuse Pleural Mesotheliomas?
Leah Lawrence
ASCO 2024: Focus on Lung Cancer
|
July 3, 2024
A pilot study evaluated neoadjuvant platinum, pemetrexed, and nivolumab followed by pleurectomy/decortication.
Read More
DeLLphi-301 Analysis: Tarlatamab Is Active in SCLC, Regardless of Baseline Brain Metastases
Leah Lawrence
ASCO 2024: Focus on Lung Cancer
|
July 2, 2024
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
Read More
KEYNOTE-671 Trial Evaluates Quality of Life With Perioperative Pembrolizumab for Early Stage, Resectable NSCLC
Leah Lawrence
ASCO 2024: Focus on Lung Cancer
|
June 24, 2024
An analysis of the phase 3 trial evaluated multiple aspects of health-related quality of life.
Read More
KRYSTAL-12: Adagrasib Significantly Improved PFS, Response in Certain Form of NSCLC
Leah Lawrence
ASCO 2024: Focus on Lung Cancer
|
June 18, 2024
The study "confirmed the role of adagrasib compared to docetaxel" in terms of PFS, response rate, and intracranial response.
Read More
Telehealth Palliative Care Visits Equivalent to In-Person for Patients With Advanced NSCLC
Leah Lawrence
ASCO 2024: Focus on Lung Cancer
|
June 10, 2024
The study findings "add critical evidence to support ongoing access to telehealth services" in these patients.
Read More
Risk Factors for Intracranial Hemorrhage in Hemophilia A Identified
Leah Lawrence
Hemophilia
|
May 21, 2024
Patients with hemophilia A who received prophylaxis had a reduced risk for ICH.
Read More
Pharmacokinetic-Guided Prophylaxis Feasible for Hemophilia A, B
Leah Lawrence
Hemophilia
|
May 14, 2024
Analysis shows pharmacokinetic-guided dosing may be effective for guiding prophylactic factor concentrate therapy.
Read More
Repeated Desmopressin Dosing Yielded Decreasing Responses in Nonsevere Hemophilia A
Leah Lawrence
Hemophilia
|
May 14, 2024
Compared with before surgery, the percentage of factor VIII increase was 42.9% at day one and 36.4% on day two.
Read More
Study Examines Factors Linked With Bleeding Risk in Severe Hemophilia
Leah Lawrence
Hemophilia
|
May 10, 2024
Free tissue factor pathway inhibitor levels were associated with thrombin generation in patients with severe hemophilia.
Read More
Attention Turns to Lung Cancer Cases in Those Who Never Smoked
Leah Lawrence
Lung Cancer
|
April 17, 2024
Just under a quarter of a million new cases of lung cancer were diagnosed in 2023, with 10-20% in non-smokers.
Read More
Targeted Therapies Continue to Infiltrate NSCLC Treatment
Leah Lawrence
Non-Small Cell Lung Cancer
|
March 15, 2024
Although most of patients with NSCLC will receive immunotherapy, a growing percentage are eligible for targeted agents.
Read More
AI Applications in Lung Cancer Ripe With Opportunity
Leah Lawrence
Lung Cancer
|
February 23, 2024
Within the lung cancer realm, different types of AI are being applied to advance the understanding of the disease.
Read More
New Trial Data Add to Exciting Options for NSCLC
Leah Lawrence
Non-Small Cell Lung Cancer
|
January 24, 2024
ESMO 2023 data reflected the fact that there are a growing number of patients with advanced NSCLC have genomic alterations.
Read More
Clearing the Air: How Climate Change Is Affecting Lung Cancer
Leah Lawrence
Lung Cancer
|
December 21, 2023
Climate change is directly relevant to lung cancer increases. This article explores the issue, and what can be done to help.
Read More